$SRPT

Sarepta Therapeutics (SRPT) expects ELEVIDYS demand to stabilize, with second-half 2026 sales modestly below first-half levels. The company is conducting studies on non-ambulatory patients and advancing FSHD and DM1 programs, with readouts expected in late 2026. Sarepta also discussed its PMO franchise's competitive position and upcoming potential competition. Key data points include potential 50% reduction in acute liver injury and over 90% correction in DUX4 gene-regulated panels.

Novartis' Phase 3 trial of del-desiran for myotonic dystrophy type 1 failed to meet its primary endpoint, video hand opening time. The company will review data and consult regulators. Del-desiran is not yet approved, and no treatment timeline is set. Novartis shares fell, along with those of Dyne and Sarepta, which are developing similar therapies.

Novartis (NVS) shares fell 14% after a late-stage trial for del-desiran in myotonic dystrophy type 1 failed its primary test, marking its second trial failure in a week. The drug showed activity on secondary measures, and the company will review data. Dyne Therapeutics (DYN) and Sarepta Therapeutics (SRPT) also declined in sympathy.

Jefferies reiterated a Buy rating and $30.00 price target for Sarepta Therapeutics (SRPT), citing potential 40% upside. The firm expects Phase I/II trial data in 2H 2026, with competitive results potentially driving significant stock movement. SRPT reported Q2 2026 earnings beating estimates, with EPS of $0.64 vs. $0.22 forecasted and revenue of $401.3M vs. $383M expected. Mizuho also reiterated an Outperform rating with a $31.00 target.

Sarepta Therapeutics (SRPT) stock fell 8.09% after Novartis (NVS) reported Phase 3 trial results for del-desiran in myotonic dystrophy type 1 (DM1) that did not meet primary endpoints. Sarepta is developing SRP-1003 for DM1, with Phase 1/2 data expected in late 2026. The company noted positive early data and potential for optimized dosing. SRPT is above short-term moving averages but below the 200-day SMA, indicating mixed signals.

Mizuho reiterated an Outperform rating and $31.00 price target on Sarepta Therapeutics (SRPT), stating the sell-off after Novartis' failed trial is excessive. The firm noted that Novartis' del-desiran showed clinical activity in secondary endpoints, which may aid Sarepta's SRP-1003 development. SRPT stock fell 10% following the news but remains up 35% over six months. The company recently reported Q2 2026 earnings of $0.64 per share, exceeding estimates, with revenue at $401.3 million.

Sarepta Therapeutics (SRPT) stock fell 7.6% in pre-market trading after Novartis' (NVS) Phase III trial failure for a neuromuscular disease treatment, impacting investor confidence in the therapeutic class. Several other pharmaceutical stocks, including AMGN, LLY, IONS, and DYN, also declined. Sarepta faces additional challenges with tightened 2026 revenue guidance and regulatory uncertainty. The broader market's risk-off tone amplified the sell-off, with SRPT trading at $20.80, below its 52-wee

President Trump may fire FDA Commissioner Marty Makary, according to the Wall Street Journal. Several biotech and pharmaceutical companies, including Replimune (REPL), uniQure (QURE), Moderna (MRNA), and others, have publicly clashed with the FDA over drug-review processes. Shares of REPL, QURE, and MRNA rose 17%, 15%, and 10% respectively at the time of writing.

Sarepta Therapeutics' INSIGHTT trial has begun testing SRP-1005, an experimental HTT-lowering drug for Huntington's disease. The trial aims to evaluate the safety and delivery method of SRP-1005, which is administered via subcutaneous injection. The study involves 32 participants and is expected to run through late 2027.

Sarepta Therapeutics rose 8.6% to $19.57 on Wednesday, driven by a broad biotech sector rally. Peer companies RXRX, TSHA, AGIO, DMRA, and SNDX also posted gains. The move reflects broader sector sentiment rather than company-specific news, with Sarepta's market cap now at $2.1 billion.